Oral self-emulsifying drug delivery systems, from biopharmaceutical to technical formulation aspects

Journal of Drug Delivery Science and Technology

Volumn 21, Issue 1, 2011, Pages 17-26

  Kuentz, M ^a  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

Author keywords

Capsule compatibility; Dilution; Dispersion; Lipolysis; Oral drug absorption; Self emulsifying drug delivery systems (SEDDS)

Indexed keywords

ALCOHOL; CARVEDILOL; CREMOPHOR; CYCLOSPORIN A; DANAZOL; DIETHYLENE GLYCOL MONOETHYL ETHER; ESSENTIAL OIL; EXCIPIENT; FENOFIBRATE; FENOGAL; GELUCIRE; HYDROXYPROPYLMETHYLCELLULOSE; LABRASOL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MEDIUM CHAIN TRIACYLGLYCEROL; OIL; OLEIC ACID; ORIDONIN; PACLITAXEL; PHENYTOIN; POLOXAMER; POLYSORBATE 20; POLYSORBATE 80; PROPYLENE GLYCOL; RITONAVIR; SOLVENT; SOYBEAN OIL; SURFACTANT; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINPOCETINE;

DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EMULSION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; LIPOLYSIS; MICROEMULSION; PHASE SEPARATION; REVIEW; TECHNOLOGY;

EID: 79952224749     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(11)50002-4     Document Type: Review

References (112)

1. Kola I., Landis J. - Can the pharmaceutical industry reduce attrition rates? - Nature Reviews Drug Discovery, 3 (8), 711-715, 2004.
2. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. - Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. - Adv. Drug. Deliv. Rev., 23 (1-3), 3-25, 1997.
3. Lipinski C. - Drug-like properties and the causes of poor solubility and poor permeability. - Journal of Pharmacological and Toxicological Methods, 44, 235-249, 2000. (Pubitemid 32239479)
4. Takagi T., Ramachandran Ch., Bermejo M., Yamashita S., Yu L., Amidon G. - A provisional biopharmaceutical classification of top 200 oral drug products in the United States, Great Britain, Spain and Japan. - Molecular Pharmaceutics, 3 (6), 631-643, 2006. (Pubitemid 46087480)
5. Strickley R.G. - Currently marketed oral lipid-based dosage forms: drug products and excipients. - In: Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water Soluble Drugs, D.J. Hauss Ed., Informa Healthcare, Inc., New York, 2007, pp. 1-31.
6. Gursoy R.N., Benita S. - Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. - Biomed. & Pharmacoth., 58, 173-182, 2004. (Pubitemid 38479922)
7. Pouton C.W. - Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying, and self-microemulsifying drug delivery systems. - Eur. J. Pharm. Sci., 11 (2), S93-S98, 2000.
8. Pouton C.W. - Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. - Eur. J. Pharm. Sci., 29, 278-287, 2006.
9. Amidon G., Lennernas H., Shah V., Crison J. - A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm. Res., 12(3), 413-420, 1995.
10. Dressman J., Amidon G., Fleisher D. - Absorption potential: Estimation of the fraction absorbed for orally administered compounds. - J. Pharm. Sci., 74 (5), 588-589, 1985.
11. Johnson K., Swindell A. - Guidance in the setting of drug particle size specifications to minimize variability in absorption. - Pharm. Res., 13 (12), 1795-1798, 1996.
12. Agoram B., Woltosz W., Bolger M. - Predicting the impact of physiological and biochemical processes on oral drug bioavailability. - Adv. Drug Deliv. Rev., 50 (S1), S41-67, 2001.
13. Willmann S., Schmitt W., Keldenich J., Lippert J., Dressman J. - A physiological model for the estimation of the fraction dose absorbed in humans. - J. Med. Chem., 47 (16), 4022-4031, 2004.
14. Jamei M., Turner D., Yang J., Neuhoff S., Polak S., Rostami-Hodjegan A., Tucker G. - Population-based mechanistic prediction of oral drug absorption. - AAPS Journal, 11 (2), 225-237, 2009.
15. Kuentz M. - Drug absorption modeling as a tool to define the strategy in clinical formulation development. - AAPS Journal, 10 (3), 473-479, 2008.
16. Kuentz M., Nick S., Parrott N., Roethlisberger D. - A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. - Eur. J. Pharm. Sci., 27 (1), 91-99, 2006.
17. Wasswik C.M., Holmen A.G., Artursson P., Bergström C.A.S. - Molecular characteristics for solid-state limited solubility. - J. Med. Chem., 51, 3035-3039, 2008.
18. Humphrey M.J. - Interface between drug discovery, ADME and pharmaceutical development. - Bull. Tech. Gattefossé, 98, 65-74, 2005.
19. Porter C.J., Kaukonen A.M., Boyd B.J., Edwards G.A, Charman W.N. - Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as medium-chain lipid-based microemulsion formulation. - Pharm. Res., 21 (8), 1405-1412, 2004.
20. Chen Y., Xianggen G.L., Chen Z., Hang J., Qin B., Chen S., Wang R. - Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. - Biol. Pharm. Bull., 31 (1), 118-125, 2008.
21. Zhang P., Liu Y., Feng N., Xu J. - Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. - Int. J. Pharm., 355, 269-276, 2008.
22. Gao P., Rush B.D., Pfund W.P., Huang T., Bauer J.M., Morozowich W., Kuo M.S., Hageman M.J. - Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. - J. Pharm. Sci., 92, 2395-2407, 2003.
23. Atef E., Belmonte A.A. - Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS). - Eur. J. Pharm. Sci., 35, 257-263, 2008.
24. Hauss D.J., Fogal S.E., Ficorilli J.V. Price C.A., Roy T., Jayaray A.A., Keirns J.J. - Lipid-based delivery system for improving the bioavailability and lymphatic transport of poorly water-soluble LTB4 inhibitor. - J. Pharm. Sci., 87 (2), 164-169, 1998.
25. Perlman M.E., Murdande S.B., Gumkowski M.J.., Shah T.S., Rodricks C.M., Thornton-Manning J., Freel D., Erhart L.C. - Development of a self-microemulsifying formulation that reduces the food effect for torcetrapib. - Int. J. Pharm., 351, 15-22, 2008.
26. Wei L., Sun P., Nie S., Pan W. - Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. - Drug Dev. Ind. Pharm., 31, 785-794, 2005.
27. Zhao Y., Wang Ch., Chow A.H.L., Ren K., Gong T., Zhang Z., Zheng Y. - Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: Formulation and bioavailability studies. - Int. J. Pharm., 383, 170-177, 2010.
28. Constantinides P.P., Welzel, G., Ellens, H., Smith, P.L., Sturgis, S., Yiv, S.H., Owen, A.B.-Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation. - Pharm. Res., 13 (2), 210-215, 1995.
29. Hong J.Y., Kim J.K., Song Y.K., Park J.S., Kim C.K. - A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. - J. Contr. Release, 110, 332-338, 2006.
30. Patel A.R., Vavia P.R. - Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. - AAPS Journal, 9 (3) E344-E352, 2007. (Pubitemid 351801762)
31. Swenson E.S., Milisen W.B., Curatolo W. - Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. - Pharm Res., 11, 1132-1142, 1994. (Pubitemid 24259853)
32. Ullrich S., Metz H., Mäder K. - Sucrose ester nanodispersions: Microviscosity and viscoelastic properties. - Eur. J. Pharm. Biopharm., 70, 550-555, 2008.
33. Brüsewitz C., Schendler A., Funke A., Wagner T., Lipp R. - Novel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds. - Int. J. Pharm., 329, 173-181, 2007.
34. Meinzer A., Mueller E.A., Niese D., Choc G., Wong R., Vonderscher J., Bernabeu M., Feutren G. - Improved oral absorption of cyclosporine by using Neoral, a microemulsion formulation. In: Lieberman R., Mukherjee A. Eds., Principles of Drug Development in Transplantation and Autoimmunity, Austin, R.G. Landes Company, 1996, pp. 259-267.
35. Kuentz M., Wyttenbach N., Kuhlmann O. - Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations- evaluation of qualitative excipient effects. - Pharm. Dev. Technol., 12, 275-283, 2007.
36. Georgakopoulos E., Farah N., Vergnault G. - Oral anhydrous non-ionic microemulsions administrated in softgel capsules. - Bull. Tech. Gattefossé, 85, 11-20, 1992.
37. Farah N., Laforet J.P., Denis J. - Self-microemulsifying drug delivery systems (SMEDDS) for improving dissolution and availability of poorly soluble actives ingredients. - Bull. Tech. Gattefossé, 87, 41-47, 1992.
38. Constantinides P.P., Welzel G., Ellens H., Smith P.L., Sturgis S.S., Yiv S.H., Owen A.B. - Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption evaluation. - Pharm. Res., 13 (2), 210-215, 1996.
39. Ali H., Nazzal M., Zaghloul A.A., Nazzal S. - Comparison between lipolysis and compendial dissolution as alternative techniques for the in vitro characterization of α-tocopherol self-emulsified drug delivery systems (SEDDS). - Int. J. Pharm., 352, 104-114, 2008.
40. Grove M., Muellertz A., Nielsen J.L., Pedersen G.P. - Bioavailability of seocalcitol. II. Development and characterization of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. - Eur. J. Pharm. Sci., 28 (3), 233-242, 2006.
41. Nielsen F.S., Gibault E., Ljusberg-Wahren H., Arleth L., Pedersen J.S., Müllertz A. - Characterization of prototype self-nanoemulsifying formulations of lipophilic compounds. - J. Pharm. Sci., 96 (4), 876-892. 2007.
42. Benameur H. - Liquid and semi-solid formulations for enhancing oral absorption. - Bull. Tech. Gattefossé, 99, 63-75, 2006.
43. Ratanabanangkoon P., Guzman H., Almarsson O., Berkovitz D., Tokarcyzk S., Straughn A.B., Chen H. - A high-throughput approach towards a novel formulation of fenofibrate in omega-3 oil. - Eur. J. Pharm. Sci., 33 (4-5), 351-360, 2008.
44. Troutman M.D., Thakker D.R. - Novel experimental parameters to quantify the modulation of absorptive and secretory transporter of compounds by P-glycoprotein in cell culture models of intestinal epithelium. - Pharm. Res., 20, 1210-1224, 2003.
45. Collet A., Tanianis-Hughes J., Hallifax D., Warhurst G. - Predicting P-glycoprotein effects on absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. - Pharm. Res., 21, 819-826, 2004.
46. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. - The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. - J. Clin. Invest., 101 (2), 289-294, 1998.
47. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. - Human P-glycoprotein transports cyclosporin A and FK506. - Journal of Biological Chemistry, 268 (9), 6077-6080, 1993. (Pubitemid 23099291)
48. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T, Kioka N., Komano T., Hori R. - Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. - Journal of Biological Chemistry, 267 (34), 24248-24252, 1992.
49. Kim W.Y., Benet L.Z. - P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. - Pharm. Res., 21 (7) 1284-1293, 2004.
50. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., Bates S.E. - The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). - Journal of Cell Science, 113 (11), 2011-2021, 2000.
51. Burger H., van Tol H., Boersma A.W., Brok M., Wiemer E.A., Stoter G., Nooter K. - Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. - Blood, 104 (9) 2940-2942, 2004. (Pubitemid 39434984)
52. Sasaki M., Suzuki H., Ito K., Abe T., Sugiyama Y. -Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). - Journal of Biological Chemistry, 277 (8), 6497-6503, 2002. (Pubitemid 34968447)
53. Huisman M., T., Smit J.W., Crommentuyn K.M., Zelcer N., Wiltshire H.R., Beijnen J.H., Schinkel A.H. - Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. - AIDS, 16 (17), 2295-2301, 2002. (Pubitemid 35449015)
54. Guo A., Marinaro W., Hu P., Sinko P.J. - Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). - Drug Metabolism and Disposition, 30 (4) 457-463, 2002.
55. Tayrouz Y., Ding R., Burhenne J., Riedel K.D., Weiss J., Hoppe-Tichy T., Haefeli W.E., Mikus G. - Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. - Clinical Pharmacology & Therapeutics, 73 (5), 397-405, 2003. (Pubitemid 36549824)
56. Hugger E.D., Novak B.L., Burton P.S., Audus K.L., Borchardt R.T. - A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. - J. Pharm. Sci., 91 (9) 1991-2002, 2002.
57. Rege B.D., Kao J.P., Polli J.E. - Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. - Eur. J. Pharm. Sci., 16 (4-5), 237-246, 2002.
58. Shono Y., Nishihara H., Matsuda Y., Furukawa S., Okada N., Fujita T., Yamamoto A. - Modulation of intestinal P-glycoprotein function by Cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. - J. Pharm. Sci., 93 (4), 877-885, 2004.
59. Cornaire G., Woodley J., Hermann P., Cloarec A., Arellano C., Houin G. - Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. - Int. J. Pharm., 278 (1), 119-131, 2004.
60. Sachs-Barrable K., Thamboo A., Lee S.D., Wasan K.M. - Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.- J. Pharm. Pharmacol. Sci., 10 (3), 2007.
61. Risovic V., Sachs-Barrable K., Boyd M., Wasan K.M. - Potential Mechanisms by Which Peceol Increases the Gastrointestinal Absorption of Amphotericin B. - Drug Dev. Ind. Pharm., 30 (7), 767-774. 2004.
62. Lo Y.L. - Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. - Biochemical Pharmacology, 60 (9), 1381-1390, 2000.
63. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. - Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. - Pharm. Res., 16 (9), 1366-1372, 1999.
64. Miller D.W., Batrakova E.V., Kabanov A.V. - Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. - Pharm. Res., 16 (3), 396-401, 1999.
65. Yamagata T., Kusuhara H., Morishita M., Jakayama K., Benameur H., Sugiyama Y. - Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. - Drug Metabolism and Disposition, 35 (7), 1142-1148, 2007. (Pubitemid 46956435)
66. Yamagata T., Morishita M., Kusuhara H.,Takayama K., Benameur H., Sugiyama Y. - Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients. - Int. J. Pharm., 370 (1-2), 216-219, 2009.
67. Lo Y.L. - Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. - J. Control. Rel., 90 (1), 37-48, 2003.
68. Bittner B., Bravo R.C.G., Kuentz M, Huwyler J.- Drug-excipient interactions by Vitamin E-TPGS: inhibition of P-glycoprotein and colonic drug absorption. - J. Drug Del. Sci. Technol., 18 (2) 145-148, 2008.
69. Colinot E.M., Baldes C., Wempe M.F., Kappl R., Huettermann J., Hyatt J.A., Edgar K.J., Schaefer U.F., Lehr C.M. - Mechanism of Inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. - Molecular Pharmaceutics, 4 (3) 465-474, 2007. (Pubitemid 46983960)
70. Zhou S., Chan E., Lee Y.L, Boelsterli U.A., Li S.C., Wang J., Zhang Q., Huang M, Xu A. - Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4., A. - Current Drug Metabolism, 5 (5), 415-442, 2004.
71. nd ACS National Meeting, San Francisco, CA, Sept. 10-14, 2006.
72. Hochman J.H., Chiba M., Nishime J., Yamazaki M., Lin J.H. - Influence of P-glycoprotein on the transport and metabolism of indinavir in caco-2 cells expressing cytochrome P-450 3A4. - Journal of Pharmacology and Experimental Therapeutics, 292 (1), 310-318, 2000. (Pubitemid 30026387)
73. Aungst B.J, Nguyen N.H, Roger N.J et al. - Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. - Int. J. Pharm., 156, 79-88, 1997.
74. Larsen A., Holm R., Pedersen M.L., Müllertz A. - Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. - Pharm. Res., 25 (12), 2769-2777, 2008.
75. Fernandez S., Rodier J.D., Ritter N., Mahler B., Demarne F., Carrière F., Jannin V. - Lipolysis of the semi-solid self-emulsifying excipients Gelucire 44/14 by digestive lipases. - Biochim. Biophys. Acta, 1781, 367-375, 2008.
76. Fernandez S., Chevrier S., Ritter N., Mahler B., Demarne F., Carrière F., Jannin V - In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizin with the self emulsifying excipients Labrasol and Gelucire 44/14. - Pharm. Res., 26 (8), 1901-1910, 2009.
77. Porter C.J., Trevaskis N.L., Charman W.N. - Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. - Nature Reviews/ Drug Discovery, 6, 231-248, 2007. (Pubitemid 46344627)
78. Porter C.J., Pouton C.W., Cuiné J.F., Charman W.N. - Enhancing intestinal drug solubilisation using lipid-based drug delivery systems. - Adv. Drug Deliv. Rev., 60, 673-691, 2008.
79. O'Driscoll C.M. - Lipid-based formulations for intestinal lymphatic delivery. - Eur. J. Pharm. Sci., 15 (5), 405-415, 2002.
80. O'Driscoll C.M. - Biopharmaceutical challenges associated with drugs with low aqueous solubility, The impact of lipid-based formulations. - Adv. Drug Deliv. Rev., 60, 617-624, 2008.
81. Wakerly M.G., Pouton C.W., Meakin B.J., Morton F.S. - Self-emulsification of oil-nonionic surfactant mixture: a proposed mechanism of action. - Am. Chem. Soc. Symp. Series, 311, 242-255, 1986.
82. Lopez-Montilla J.C., Herrera-Morales P.E., Pandey S., Shah D.O. - Spontaneous emulsification. Mechanisms, physicochemical aspects, modeling, and applications. - Journal of Disp. Sci. Technol., 23 (1-3), 219-268, 2002. (Pubitemid 34788947)
83. Kuentz M., Cavegn M. - Critical concentrations in the dilution of oral self-microemulsifying drug delivery systems. - Drug. Dev. Ind. Pharm., 36 (5) 531-538, 2010.
84. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., Dressman J.B. - Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. - Pharm. Res., 15(5), 698-705, 1998.
85. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., Reppas C. - Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. - J. Pharm. Pharmacol., 56, 453-462, 2004.
86. Vertzoni M., Dressman J., Butler J., Hempenstall J., Reppas C. - Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. - Eur. J. Pharm. Biopharm., 60, 413-417, 2005.
87. Ditner C., Bravo R., Imanidis G., Kuentz M. - A systematic dilution study of self-microemulsifying drug delivery systems in artificial intestinal fluid using dynamic laser light backscattering. - Drug Dev. Ind. Pharm., 35, 199-208, 2009.
88. Zidan A.S., Sammour O.A., Hammad M.A., Megrab N.A., Habib M.J., Khan M.A. - Quality by design: understanding the product variability of a self-nanoemulsified drug delivery system of cyclosporine A. - J. Pharm. Sci., 96 (9), 2409-2423, 2007.
89. Shah N.H., Carvajal M.T., Patel C.I., Infeld M.H., Malick A.W. - Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. - Int. J. Pharm., 106, 15-23, 1994.
90. Arnold Y., Bravo Goncales R., Versace H., Kuentz M. - Comparison of different in vitro tests to assess oral lipid-based formulations using a poorly soluble acidic drug. - J. Drug Deliv. Sci. Technol., 20 (2), 143-148, 2010.
91. Zangenberg N.H., Müllertz A., Kristensen H.G., Hovgaard L. - A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. - Eur. J. Pharm. Sci., 14, 115-122, 2001.
92. Zangenberg N.H., Müllertz A., Kristensen H.G., Hovgaard L. - A dynamic in vitro lipolysis model. II. Evaluation of the model. - Eur. J. Pharm. Sci., 14, 237-244, 2001.
93. Sek L., Porter C.J.., Kaukonen A.M., Charman W. - Evaluation of the in vitro digestion profiles for long and medium chain triglycerides and the phase behaviour of the lipolytic products. - J. Pharm. Pharmacol., 54, 29-41, 2002.
94. Porter C.J., Kaukonen A.M., Taillardat-Bertschinger A., Boyd B.J., O'Connor J.M., Edwards G.A., Charman W. - Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Study with halofantrine. - J. Pharm. Sci., 93 (5), 1110-1121, 2004.
95. Kaukonen A.M., Boyd B.J., Porter C.J., Charman W.N. - Drug solubilization behaviour during in vitro digestion of simple triglyceride lipid solution formulations. - Pharm. Res., 21, 245-253, 2004.
96. Kaukonen A.M., Boyd B.J, Charman W.N., Porter C.J. - Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. - Pharm. Res., 21, 254-260, 2004.
97. Cuiné J.F., Charman W.N., Pouton C.W., Edwards G.A., Porter C.J. - Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based systems reduces oral bioavailability in beagle dogs. - Pharm. Res., 24 (4), 748-757, 2007.
98. Gad S.C., Cassidy C.D., Aubert N., Spainhour B., Robbe H. - Nonclinical vehicle use in studies by multiple routes in multiple species. - Int. J. Tox., 25, 499-521, 2006.
99. Jannin V., Musakhanian J., Marchaud D. - Approaches for the development of solid and semi-solid lipid-based formulations. - Adv. Drug. Deliv. Rev., 60, 734-746, 2008.
100. Tang B., Cheng G., Gu J.C., Xu C.H. - Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. - Drug Discovery Today, 13 (13/14), 606-612, 2008.
101. Cole E.T.- Liquid-filled as sealed hard gelatin capsules. - Bull. Tech. Gattefossé, 89, 15-21, 1999.
102. Cole E.T., Cade D., Benameur H. - Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. - Adv. Drug Del. Rev., 60 (6), 747-756, 2008.
103. Kontny M.J., Mulski C.A. - Gelatin capsule brittleness as a function of relative humidity at room temperature. - Int. J. Pharm., 54, 79-85, 1989.
104. Kuentz M., Röthlisberger D. - Determination of the optimal amount of water in liquid-fill masses for hard gelatin capsules by means of texture analysis and experimental design. - Int. J. Pharm., 236, 145-152, 2002.
105. Mei X., Etzler F.M., Wang Z. - Use of texture analysis to study hydrophilic solvent effects on the mechanical properties of hard gelatin capsules. - Int. J. Pharm., 324, 128-135, 2006.
106. Chen F.J., Etzler F.M., Ubben J., Birch U., Zhong L., Schwabe R., Dudhedia M.S. - Effects of lipophilic components on the compatibility of lipid-based formulations with hard gelatin capsules. - J. Pharm. Sci., 99 (1), 128-141, 2010.
107. 1H NMR as a new method to monitor softening of gelatin and HPMC capsule shells. - Drug Dev. Ind. Pharm., 32 (10), 1165-1173, 2006.
108. Cadé D., Madit N. - Liquid filling in hard gelatin capsules - preliminary steps. - Bull. Tech. Gattefossé, 89, 15-19, 1996.
109. Walters P.A., Rowley G., Pearson J.T., Taylor C.J. - Formulation and physical properties of thixotropic gels for hard gelatin capsules. - Drug Dev. Ind. Pharm., 18 (15), 1613-1631, 1992.
110. Kuentz M. - Thixotropic oil-based vehicle for pharmaceutical compositions. - US Pat. Appl. Publ. - CODEN: USXXCO US 2003054043 A1 20030320, 6pp, 2003.
111. Rowley G., Hawley A.R., Dobson C.L., Chatham S.- Rheology and filling characteristics of particulate dispersions in polymer melt formulations for liquid fill hard gelatin capsules. - Drug. Dev. Ind. Pharm., 24 (7), 605-611, 1998.
112. Kattige A., Rowley G. - Influence of rheological behaviour of particulate/polymer dispersions on liquid-filling characteristics for hard gelatin capsules. - Int. J. Pharm., 316, 74-85, 2006.